Glutathione in childhood acute leukaemias

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 211-216

  Kearns, P ^a,b   Pieters, R ^a   Rottier, M M A ^a   Veerman, A J P ^a   Schmiegalow, K ^c   Pearson, A D J ^b   Hall, A G ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Rigshospitalet   (Denmark)

Author keywords

Childhood leukaemia; Drug resistance; Glutathione; Prognostic indicators

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLAST CELL CRISIS; BLOOD; BONE MARROW CELL; CELL CULTURE; CELL SURVIVAL; CHILD; DRUG EFFECT; FEMALE; HUMAN; INFANT; MALE; METABOLISM; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BONE MARROW CELLS; CELL SURVIVAL; CHILD; CHILD, PRESCHOOL; FEMALE; GLUTATHIONE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0032610935     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_23     Document Type: Article

References (21)

1. Cotes J. E., Kantarjian H. M. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer, 1995, 76, 2395-2417.
2. Pieters R., Huismans D. R., Leonen A. H., Hahlen K., Van Der Does-van Den Berg A., Van Wering E. R. and Veerman A. J. P. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet, 1991, 338, 399-403.
3. O'Brien M. L. and Tew K. D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer, 1996, 967-978.
4. Frischer H., Kennedy E. J., Chigurupati R. and Sivarajan M. Glutathione, cell proliferation, and 1,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia. Journal of Clinical Investigation, 1993, 92, 2761-2767.
5. Watson R. W. G., Rotstein O. D., Nathens A. B., Dackiw A. P. B. and Marshall J. C. Thiol-mediated redox regulation of neutrophil apoptosis. Surgery, 1996, 120, 150-158.
6. Ozols R. F., O'Dwyer P. J., Hamilton T. C. and Young R. C. The role of glutathione in drug resistance. Cancer Treat. Rev., 1990, 17, 45-50.
7. Ferraris A. M., Rolfo M., Mangerini R. and Gaetani G. F. Increased glutathione in chronic lymphocytic leukemia lymphocytes, Am. J. Hematol., 1994, 47, 237-238.
8. Maung Z. T., Reid M. M., Matheson E., Taylor P. R. A., Proctor S. J. and Hall A. G. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: Preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br. J. Haematol., 1995, 91, 93-100.
9. Paydas S., Yuregir G. T., Sahin B., Seyrek E. and Burgut R. Intracellular glutathione content in leukemias. Oncology, 1995, 52, 112-115.
10. Kearns P. R. and Hall A. G. Microtitre plate technique for the measurement of glutathione in fresh and cryopreserved lymphoblasts using the enzyme recycling method. Methods in Molecular Medicine, 1999, (in press).
11. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem., 976, 72, 248-254.
12. Terradez P., Asensi M., Lasso del la Vega M. C., Puertes I. R., Viǹa J. and Estrela J. M. Depletion of tumour glutathione in vivo by buthionine sulphoximine: Modulation by the rate of cellular proliferation and inhibition of cancer growth. Biochem. J., 1993, 292, 477-483.
13. Poot M., Teubert H., Rabinovitch P. S. and Kavanagh T. J. De novo synthesis of glutathione is required for both entry into and progression through the cell cycle. J. Cell. Physiol., 1995, 163, 555-560.
14. Frischer H., Kennedy E. J., Chigurupati R. and Sivarajan M. Glutathione, cell proliferation, and 1,3-bis-(2-chloroethyl)- 1-nitrosourea in K562 leukemia. J. Clin. Invest., 1993, 92, 2761-2767.
15. Kavanagh T. J., Grossmann A., Jaecks E. P., Jinneman J. C., Eaton D. L., Martin G. M. and Rabinovitch P. S. Proliferative capacity of human peripheral blood lymphocytes sorted on the basis of glutathione content. J. Cell. Physiol., 1990, 145, 472-480.
16. Ngo E. O. and Nutter L. M. Status of glutathione and glutathione-metabolizing enzymes in menadione-resistant human cancer cells. Biochem. Pharmacol., 1994, 47, 421-424.
17. Scarffe J. H., Hann I. M., Evans D. I. K., Morris-Jones P., Palmer M. K., Lilleyman J. S. and Crowther D. Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood. Br. J. Cancer, 1980, 41, 764-771.
18. Siemann D. W. and Beyers K. L. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. British Journal of Cancer, 1993, 68, 1071-1079.
19. Medh R. D., Gupta V. and Awasthi Y. C. Reversal of melphalan resistance in vivo and in vitro by modulation of glutathione metabolism. Biochem Pharmacol., 1991, 42, 439-441.
20. Ozols R. F., Louie K. G., Plowman J., Behrens B. C., Fine R. L., Dykes D. and Hamilton T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol., 1987, 36, 147-153.
21. O'Dwyer P. J., Hamilton T. C., Young R. C., LaCreta F. P., Carp N., Tew K. D., Padavic K., Comis R. L. and Ozols R. F. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J. Natl. Cancer Inst., 1992, 84, 264-267.